ProfileGDS5678 / 1423941_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 86% 86% 85% 86% 88% 87% 86% 83% 86% 86% 86% 86% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5235786
GSM967853U87-EV human glioblastoma xenograft - Control 26.5103186
GSM967854U87-EV human glioblastoma xenograft - Control 36.5029286
GSM967855U87-EV human glioblastoma xenograft - Control 46.5181485
GSM967856U87-EV human glioblastoma xenograft - Control 56.5810486
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5896388
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.576687
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4544486
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.07783
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5022986
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4967986
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5190986
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4739886
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.42286